Skip to main content
MedPathMedPath Home
Clinical Trials/JPRN-UMIN000006340
JPRN-UMIN000006340
Completed
未知

Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation (NEJ009) - Gefitinib vs Gefitinib plus chemotherapy for EGFR-mutated NSCLC (NEJ009)

orth-East Japan Study Group0 sites345 target enrollmentOctober 1, 2011
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionson-small cell lung cancer

Overview

Phase
未知
Intervention
Not specified
Conditions
on-small cell lung cancer
Sponsor
orth-East Japan Study Group
Enrollment
345
Status
Completed
Last Updated
2 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 1, 2011
End Date
September 18, 2019
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
orth-East Japan Study Group

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • •1\. NSCLC harboring T790M mutation 2\. With massive effusion that require drainage 3\. With symptomatic brain metastasis 4\. With severe co\-morbidities 5\. With ineligible conditions judged by the attending physician

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 3
A phase III study comparing gefitinib and inserted cisplatin and pemetrexed with gefitinib as a first-line treatment for patients with advanced non-squamous non-small-cell lung cancer harboring EGFR activating mutation (JCOG1404/WJOG8214L, AGAIN study)advanced non-squamous non-small cell lung cancer harboring EGFR mutaiton
JPRN-UMIN000020242Japan Clinical Oncology Group (JCOG)500
Completed
Phase 3
Randomized Phase III Trial Comparing Gefitinib with Carboplatin/Paclitaxel in Previously Untreated Advanced Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Gene Mutations
JPRN-C000000376EJ Gefitinib Study Group320
Completed
Not Applicable
Follow up analysis of phase III study of gefitinib versus erlotinib in patients with advanced lung adenocarcinoma.Previously treated advanced lung adenocarcinoma
JPRN-UMIN000030082West Japan Oncology Group561
Completed
Phase 3
Phase III study of gefitinib versus erlotinib in patients with previously treated lung adeno carcinomaPreviously treated lung adeno carcinoma
JPRN-UMIN000002014West Japan Oncology Group560
Completed
Not Applicable
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancer
JPRN-UMIN000004296Okayama Lung Cancer Study Group42